Key Takeaways
- MedPharm Research’s application for DEA cannabis federal registration was denied due to its connection with related companies involved in unauthorized marijuana manufacturing.
- The DEA can consider the conduct of a company’s parent and sister entities when evaluating registration applications, as demonstrated in MedPharm’s case.
- With the new Schedule III pathway, state-licensed medical marijuana operators can utilize existing credentials for an expedited DEA registration process.
- Adult-use cannabis still remains in Schedule I, and companies must demonstrate clear operational separation between medical and recreational activities.
- Cannabis companies seeking registration should document separation thoroughly and be prepared for DEA scrutiny regarding shared facilities and leadership.
Cannabis companies have spent months watching the federal registration door open wider than it has in half a century. A new DEA order involving MedPharm Research LLC is a reminder that the door swings both ways.
DEA denied the Denver company’s 2016 application to become a registered bulk manufacturer of Schedule I marijuana, a case that had sat dormant for years before the agency moved to close it this fall. MedPharm Research itself wasn’t accused of doing anything wrong. The problem, according to DEA, belonged to its corporate family.
That is the real story here. It isn’t really about one company losing one old application. It’s about whether cannabis businesses entering the new federal medical system can wall off those operations cleanly enough from state-legal recreational activity that DEA still treats as unlawful under federal law. For any vertically integrated operator eyeing the Schedule III pathway, that question just got a lot more concrete.
What Happened in the MedPharm Research Case
MedPharm Research applied for a DEA manufacturer registration back in September 2016. DEA issued an Order to Show Cause in September 2025, alleging the registration would conflict with the public interest. MedPharm Research never filed an answer or requested a hearing, so under 21 CFR 1301.43, the agency treated every factual allegation in that order as admitted by default.
Those admitted facts told a specific story. MedPharm Research is a wholly owned subsidiary of MedPharm Holdings LLC, which does business as Bud & Mary’s Cannabis. MedPharm Holdings also owns a second subsidiary, MX LLC, and the same CEO oversees both companies.
According to DEA, neither MedPharm Research, MedPharm Holdings, nor MX has ever held a DEA registration to manufacture marijuana, despite the fact that MX has held Colorado state licenses and sold marijuana into both the medical and recreational markets since 2016.
MedPharm Research had proposed running its federal research operation out of the same facility where MX was already cultivating marijuana for both markets. DEA didn’t need to find wrongdoing at the applicant level. It found enough at the parent and sibling level to deny the application entirely.
Why DEA Can Look Past the Applicant’s Own Conduct
Federal manufacturer registrations for Schedule I and II substances require DEA to find that registration is “consistent with the public interest,” a standard drawn from 21 U.S.C. 823(a). The statute lists six factors, including effective controls against diversion, compliance with state and local law, and the applicant’s history of compliance with the Controlled Substances Act.
DEA’s order leaned on precedent allowing the agency to “look behind an entity’s ownership structure” to evaluate the conduct of the people controlling the business, citing its 2012 decision in Pharmboy Ventures Unlimited. In MedPharm Research’s case, that meant examining what the parent company and its sister entity were doing, not just what the applicant itself had done. Because one CEO controlled all three entities, DEA treated the recreational manufacturing happening under MX as directly relevant to whether MedPharm Research’s registration would serve the public interest.
The agency was blunt about the consequence. Manufacturing marijuana without DEA registration violates the CSA. Manufacturing marijuana for the recreational market, DEA wrote, “constitutes diversion of a Schedule I controlled substance,” regardless of which entity in the corporate family actually held the license. That diversion finding, combined with a decade of unregistered activity, was enough to sink the application on its own. The applicant’s own conduct was almost beside the point.
The New Schedule III Pathway, and Where It Draws the Line
This case unfolds against the backdrop of a genuinely significant regulatory shift. In April 2026, the Department of Justice issued a final order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, effective April 22, 2026. For state-licensed medical operators, that order created an expedited registration pathway under 21 CFR Part 1301. Operators can submit existing state credentials as evidence of state-law authorization, and DEA must grant registration unless doing so would conflict with the public interest or U.S. treaty obligations.
The practical upside is real. Registered operators gain reduced regulatory burden, a path to import and export permits, and relief from the Section 280E tax penalty that has squeezed cannabis businesses for years. Early applicants can even operate under their state license while DEA reviews their application.
But the order left one category entirely untouched. Adult-use cannabis remains in Schedule I. Only marijuana covered by an FDA approval or a state medical license qualifies for the new framework. Every other cannabis product and every other license type stays exactly where it was.
That gap is where the MedPharm Research case becomes instructive rather than incidental. Analysis of the April order flagged this directly: operators in dual-license states where medical and adult-use activities are commingled “will face difficult questions about whether they can achieve sufficient separation to qualify.” MedPharm Research is a preview of how DEA answers that question when a company doesn’t achieve that separation, or doesn’t defend itself when asked to prove it did.
How Separate Does Separate Have to Be?
This is the question every multistate or vertically integrated cannabis company should be sitting with right now. DEA has made clear it will examine parent companies, sister companies, and shared leadership when weighing a registration application. Owning a medical license through one entity doesn’t insulate that entity from scrutiny if an affiliate under common control is manufacturing or selling into the recreational market.
Corporate separation on paper may not be enough. MedPharm Research and MX shared a facility and a CEO. DEA treated that operational overlap as evidence the two businesses weren’t meaningfully separate at all, regardless of how the entities were structured on paper. Companies hoping to rely on a clean subsidiary structure should expect DEA to look at where operations actually happen, who actually makes decisions, and how tightly the regulated and unregulated sides of the business are intertwined in practice.
There’s also a timing lesson buried in the procedural history. MedPharm Research’s application sat open for nearly a decade, through multiple rounds of DEA information requests, before the agency finally acted. Companies with old or pending applications shouldn’t assume inactivity means safety. DEA can, and did, use that extended window to build a record on affiliated conduct and then close the file through a default order once the applicant failed to respond.
None of this means the Schedule III pathway is unworkable for companies with recreational operations somewhere in their corporate family. It means the separation needs to be more than a line on an org chart. Operators considering registration should take a hard look at shared facilities, shared leadership, and shared licenses before filing, not after DEA raises the question.
What This Means for Cannabis Companies Weighing Federal Registration
DEA included a notable footnote in the MedPharm Research order. Denial of this particular application, the agency wrote, doesn’t prevent MedPharm Research from applying through the new state-license framework if it qualifies. That’s a meaningful signal. DEA isn’t treating this as a permanent bar from the federal system. It’s treating it as a finding about one specific application, built on one specific factual record, under the older Schedule I framework that applied before the Schedule III pathway existed.
That leaves an open question for every company watching this case: would the same facts produce a different outcome under the new expedited medical registration process, where state licensure itself carries more weight as evidence of compliance? DEA hasn’t answered that yet, and the agency’s own order suggests it’s prepared to consider a fresh application on its own terms.
What companies can take from this now is narrower but still useful. The public interest standard under 21 U.S.C. 823 gives DEA real latitude to consider conduct well outside the four corners of an application. Shared ownership, shared facilities, and shared leadership between a federally compliant entity and a state-recreational entity are all fair game. Before filing, operators should map out exactly how separate their medical operations are from any adult-use activity in the same corporate family, document that separation clearly, and be prepared to answer for it if DEA asks. The companies that treat “separate” as a genuine operational standard, not just a paperwork exercise, will be in a stronger position than the ones that find out the hard way what DEA considers close enough to count.
Frequently Asked Questions
The DEA denied MedPharm Research’s application because its parent and sister companies had illegally manufactured and sold marijuana in Colorado’s recreational market without DEA registration. This was deemed contrary to the public interest. MedPharm Research’s failure to respond to the Order to Show Cause meant the allegations were automatically admitted.
The DEA can examine a company’s full ownership structure, including parent and sister entities, when evaluating a registration application. The MedPharm Research case demonstrated this clearly — the DEA factored in the recreational marijuana manufacturing of related entities, even though those entities were not the ones applying for registration.
The April 2026 Schedule III order only covers FDA-approved or state-licensed medical marijuana. Recreational cannabis remains Schedule I, and the DEA continues to treat its manufacture and sale as a federal violation.
The DEA focuses on operational realities, not corporate paperwork, when evaluating cannabis-related federal registrations. Shared facilities, leadership, and licensing between medical and recreational entities can signal insufficient separation. To improve their chances of approval, companies should establish and document distinct facilities, decision-making structures, and licensing before applying.
